ICER Publishes Draft Evidence Report on Asthma Drug; Register Now for October Webinar
September 30, 2021
The Institute for Clinical and Economic Review (ICER) has published its Draft Evidence Report for severe asthma drug tezepelumab. The report includes efficacy and cost-effectiveness analyses of the monoclonal antibody.
“On October 6, 2021, as part of ICER’s Early Insights Webinar Series, ICER’s President Steven D. Pearson, MD, MSc, will present the initial findings of this draft report.” Learn more here.
(Source: ICER, 9/16/21)